Gaps in current product labels and a lack of detailed clinical guidelines leaves clinicians' questions on the practical management of patients receiving cladribine tablets for the treatment of relapsing multiple sclerosis (MS) unanswered. We describe a consensus-based programme led by international MS experts with the aim of providing recommendations to support the use of cladribine tablets in clinical practice.
Sørensen, P.s., Centonze, D., Giovannoni, G., Montalban, X., Selchen, D., Vermersch, P., et al. (2020). Expert opinion on the use of cladribine tablets in clinical practice. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 13, 1756286420935019 [10.1177/1756286420935019].
Expert opinion on the use of cladribine tablets in clinical practice
Centonze, Diego;
2020-06-24
Abstract
Gaps in current product labels and a lack of detailed clinical guidelines leaves clinicians' questions on the practical management of patients receiving cladribine tablets for the treatment of relapsing multiple sclerosis (MS) unanswered. We describe a consensus-based programme led by international MS experts with the aim of providing recommendations to support the use of cladribine tablets in clinical practice.| File | Dimensione | Formato | |
|---|---|---|---|
|
1756286420935019.pdf
solo utenti autorizzati
Licenza:
Non specificato
Dimensione
300.84 kB
Formato
Adobe PDF
|
300.84 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
